Kady Cherry

[Janna Mittakkanen @J_Mittakkanen]

10Y at 4.52%, 30Y over 5% 😅 Bonds crashing, gold & silver taking a hit… but honestly, this looks like a prime setup. I’m keeping some $XAU/$XAG ready, if yields spike more, metals could pop

[Kady Cherry @KCherry99788]

@ManchesterUtd81 @JackFarley96 Its amazing how undervalued alot of the miners with many a bit below historical PE with best balance sheets ever.

[Peter Schiff @PeterSchiff]

Bond yields broke out just as I predicted they would. Today's selloff in gold, and especially the $6.70 plunge in silver, is a great buying opportunity, as investors who expected bond yields to fall have no idea what higher yields portend for inflation and precious metals.

[Anshul Dhir @anshuldhir_]

Gold down 2.2% this week and I keep coming back to the same thought.

Silver especially sits at a rare intersection: monetary asset, industrial input, and a nascent role in the clean energy buildout. The demand stack is more layered than it looks.

[Michael Boyd @MichaelBoy64231]

$IOVA what it’s all about, in case we’ve lost sight due to the day-day noise

[Kady Cherry @KCherry99788]

@derrick_dao @WhaleInsider Its also short term influence and worries about India increased tariffs on gold and silver. Still very bullish long term both

[Derrick Dao @derrick_dao]

Silver at $83 is still 2x the 2024 average. A 5% drop on this tape is COMEX short-side unwind and CTA position trimming — not a change in physical. Solar + EV demand runs >25% above the pre-2022 baseline. ~70% of supply comes as byproduct of copper, zinc and gold mines, so primary doesn't respond to silver prices.

[multibagg.ai @MultibaggAI]

INDIA'S GEMS & JEWELLERY EXPORTS FELL 9.07% YOY TO $2.45B IN APR 2026, PRESSURED BY WEAK DEMAND AND PRICE VOLATILITY. DIAMOND AND PLAIN GOLD SHIPMENTS SLUMPED, WHILE SILVER AND PLATINUM JEWELLERY ROSE.

[John @John6088006397]

@BIOTECHSCANNER I'm not like most investors I look at the money I put into biotech specifically cancer research biotech as if I was tidying in a church and I expect expect nothing back. This is purely the reason why I do it so someone beats cancer and this is the greatest reason for me to

[Jerom10_21 💛🖤 ᵗⁱˡ @Jerom10_21]

$IOVA - FDA DESIGNATIONS 👌

Melanoma (C-144-01)
RMAT, Fast Track, Orphan Drug, Priority Review, Accelerated approval in the US.

Lung cancer (IOV-LUN-202)
Fast Track Designation
Available for registration application.

Cervical cancer (C-145-04)
Breakthrough Therapy Designation.

[Dan Sfera @Dansfera]

@BiotechFQ clean CRL plus a 50% rep expansion before launch tells you everything about how aqst is reading the timeline. they are building for ship, not stall.

[Biotech FQ @BiotechFQ]

$AQST Q1 results
The CRL did not identify any chemistry, manufacturing, or controls (CMC) deficiencies, and clinical results supporting comparability to auto-injectors were not questioned.
# sales representatives - increase of 50% to 75. https://t.co/KDI3FIMKLy

[BIOTECH SCANNER @BIOTECHSCANNER]

$IOVA - Absolutely love that they gave a tour of iCTC to these patients who were practically cured from their cancer. Mostly of these patients were on their way to hospice.

https://t.co/prEyrbM8Zt

[Kady Cherry @KCherry99788]

@Dansfera @Finsee_main $Zvra also a good value play too

[Dan Sfera @Dansfera]

@Finsee_main 66% revenue growth (despite the 1 time royalty from $zvra formerly kempharm). still great news and speaks to their historical capability to execute. make it make sense for the bears.

[Finsee @Finsee_main]

$AQST Q1 2026 earnings: Revenues Surge as Aquestive Buys Time for Anaphylm

Aquestive delivered a remarkably clean quarter while navigating the delay of its flagship Anaphylm product. Revenue skyrocketed 66% year-over-year to $14.4 million, driven by a massive jump in royalty payments. Crucially, the company slashed its net loss by 65% to $8.1 million. With a new $150 million debt facility securing its runway, Aquestive is preparing to increase its planned sales force by 50% and target a Q3 2026 NDA resubmission. The fundamental story remains stable: execute the FDA requests and prepare the balance sheet for a transformational launch.

Full article with charts - link in bio

🐂 𝐁𝐮𝐥𝐥 𝐂𝐚𝐬𝐞
• 𝐂𝐥𝐞𝐚𝐫 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐏𝐚𝐭𝐡 — The FDA Type A meeting is complete, aligning on human factors and PK study designs without any new CMC or clinical comparability hurdles. The Q3 2026 resubmission target is locked in.
• 𝐑𝐨𝐲𝐚𝐥𝐭𝐲 𝐄𝐧𝐠𝐢𝐧𝐞 𝐅𝐢𝐫𝐢𝐧𝐠 — License and royalty revenues exploded from $0.8M to $5.4M. This high-margin cash flow acts as a powerful bridge while Anaphylm waits for approval.

🐻 𝐁𝐞𝐚𝐫 𝐂𝐚𝐬𝐞
• 𝐄𝐱𝐩𝐚𝐧𝐝𝐞𝐝 𝐋𝐚𝐮𝐧𝐜𝐡 𝐁𝐮𝐫𝐧 — Management increased the planned sales force from 50 to 75 reps. If FDA review stretches into 2027, this bloated cost structure will torch the newly acquired cash runway.
• 𝐄𝐱𝐞𝐜𝐮𝐭𝐢𝐨𝐧 𝐓𝐢𝐠𝐡𝐭𝐫𝐨𝐩𝐞 — Two clinical studies must be completed flawlessly and rapidly to meet the Q3 2026 resubmission timeline. Any misstep pushes revenue generation out indefinitely.

⚖️ 𝐕𝐞𝐫𝐝𝐢𝐜𝐭: 🟢
Bullish. Management is executing exactly what they promised after the CRL setback: securing cheap debt, shrinking the baseline cash burn, and advancing the FDA dialogue. The core asset remains highly valuable.

𝐊𝐞𝐲 𝐓𝐡𝐞𝐦𝐞𝐬

🟢🟢 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐋𝐢𝐜𝐞𝐧𝐬𝐞 𝐚𝐧𝐝 𝐑𝐨𝐲𝐚𝐥𝐭𝐲 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 [NEW]
High-margin revenue is accelerating rapidly. License and royalty revenue surged to $5.4 million from $0.8 million a year ago, primarily driven by Zevra. This transforms the income statement, dramatically lowering the cash burn right when the company needs to fund new Anaphylm clinical trials.

🟢 𝐁𝐚𝐬𝐞 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐕𝐨𝐥𝐮𝐦𝐞 𝐑𝐞𝐜𝐨𝐯𝐞𝐫𝐲
The legacy CDMO business is stable to accelerating. Manufacture and supply revenue rose 22% YoY to $8.8 million, driven by an increase in total doses shipped (33 million vs 27 million in Q1 2025). Strength in Suboxone and other partnerships ensures the lights stay on without eating into launch capital.

🟢 𝐀𝐝𝐫𝐞𝐧𝐚𝐕𝐞𝐫𝐬𝐞 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: 𝐀𝐐𝐒𝐓-𝟏𝟎𝟖 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 [NEW]
Aquestive is pushing the AdrenaVerse platform forward. The Phase 1 trial for the AQST-108 topical gel found no systemic absorption issues and successfully identified a biomarker signal suppressing the TSLP cytokine (involving JAK1/JAK2 pathways). This specific innovation opens the door to massive dermatological markets like atopic dermatitis.

🔴 𝐒𝐚𝐥𝐞𝐬 𝐅𝐨𝐫𝐜𝐞 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐂𝐨𝐧𝐭𝐫𝐚𝐝𝐢𝐜𝐭𝐬 𝐂𝐚𝐬𝐡 𝐍𝐚𝐫𝐫𝐚𝐭𝐢𝐯𝐞 [NEW]
Management highlights their new $150M Oaktree debt and 'well-capitalized' status for launch. However, in the same breath, they announced a 50% increase in the planned Anaphylm field force (from 50 to 75 sales reps). Pushing fixed commercial costs higher while the drug's approval is delayed until at least late 2026/early 2027 creates a significant contradiction that threatens the cash runway if revenues don't materialize instantly upon launch.

⚪ 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐄𝐱𝐞𝐜𝐮𝐭𝐢𝐨𝐧 𝐑𝐢𝐬𝐤 𝐑𝐞𝐦𝐚𝐢𝐧𝐬 𝐇𝐢𝐠𝐡
The path forward requires new human factors validation and a new PK study. While the Type A FDA meeting provided clarity, any patient dropouts, logistical delays, or slightly off-target PK data will shatter the Q3 2026 resubmission timeline. The risk profile is stable, but absolute execution is required.

⚪ 𝐒𝐮𝐛𝐨𝐱𝐨𝐧𝐞 𝐒𝐮𝐧𝐬𝐞𝐭 𝐀𝐥𝐰𝐚𝐲𝐬 𝐋𝐨𝐨𝐦𝐢𝐧𝐠
While Q1 saw a bump in Suboxone revenues, the long-term trend for this legacy asset is a gradual, terminal decline. Aquestive must continue outrunning this attrition with newer products like Ondif, Sympazan, and Emylif.

🟢 𝐈𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐭𝐨 𝐌𝐚𝐜𝐫𝐨 𝐓𝐚𝐫𝐢𝐟𝐟 𝐒𝐡𝐨𝐜𝐤𝐬
In a volatile geopolitical environment, Aquestive confirmed its U. S.-domiciled intellectual property and U. S.-based manufacturing leave its supply chain completely unaffected by proposed and implemented government tariffs. This provides exceptional margin visibility compared to peers heavily reliant on Asian or European API sourcing.

𝐎𝐭𝐡𝐞𝐫 𝐊𝐏𝐈𝐬

𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐄𝐱𝐩𝐞𝐧𝐬𝐞𝐬 (𝐒𝐆&𝐀): $11.0 million
Decelerating aggressively. SG&A dropped 42% from $19.1 million in 25Q1. This was largely due to the non-repeat of a $4.3M Anaphylm PDUFA fee, alongside $3.4M in lower legal fees and $2.0M less in commercial spending. The company is successfully clamping down on costs during the regulatory delay.

𝐂𝐚𝐬𝐡 𝐚𝐧𝐝 𝐄𝐪𝐮𝐢𝐯𝐚𝐥𝐞𝐧𝐭𝐬: $110.7 million
Stable position. Down slightly from $121.1 million at year-end 2025, but robust enough to weather the Anaphylm delay. The new $150M Oaktree debt facility saves $45M in near-term principal payments, pushing maturities out to 2031 and unlocking optionality.

𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞

𝐅𝐘𝟐𝟔 𝐓𝐨𝐭𝐚𝐥 𝐑𝐞𝐯𝐞𝐧𝐮𝐞: $46 - $50 million
Stable. Guidance implies an accelerating run rate to hit the $48M midpoint. Q1 delivered $14.4M, meaning the company is currently pacing ahead of its own full-year implied quarterly average ($12M). Achievement is highly likely.

𝐅𝐘𝟐𝟔 𝐍𝐨𝐧-𝐆𝐀𝐀𝐏 𝐀𝐝𝐣𝐮𝐬𝐭𝐞𝐝 𝐄𝐁𝐈𝐓𝐃𝐀 𝐋𝐨𝐬𝐬: $30 - $35 million
Stable. The maintained guidance midpoint of -$32.5M indicates management expects spending to ramp back up in the second half of the year to support the new Anaphylm clinical trials and expanded sales force preparations.

𝐊𝐞𝐲 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬

𝐒𝐚𝐥𝐞𝐬 𝐅𝐨𝐫𝐜𝐞 𝐑𝐎𝐈
What specific market data drove the decision to increase the Anaphylm launch field force by 50% from 50 to 75 reps, and how does this alter your break-even timeline post-approval?

𝐀𝐐𝐒𝐓-𝟏𝟎𝟖 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐏𝐢𝐯𝐨𝐭
The AQST-108 update mentioned utilizing an atopic dermatitis study design. Does this represent a permanent shift away from alopecia areata as the lead indication, or are you pursuing both in parallel?

𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐝 𝐑𝐞𝐯𝐢𝐞𝐰 𝐂𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐜𝐞
You plan to request an accelerated FDA review upon Anaphylm's resubmission in Q3. Given the historical strictness of this division, what specific precedents give you confidence this request might be granted?

[Jerom10_21 💛🖤 ᵗⁱˡ @Jerom10_21]

$IOVA ASCO Annual Meeting (May 29 - June 2, 2026): This is the world's largest and most important congress for cancer research, where Iovance traditionally shares updates on its pipeline, including next-generation treatments such as IOV-4001.

[Kady Cherry @KCherry99788]

@DividendKoenig @42traders Also the patent cliff worries for Keytruda greatly exaggerated

[Oakland Clones @oakland_clones]

$iova Every commercial infusion not OOS (R&D expense) or patient drop off (COS expense) hugely benefits the bottom line.

Said differently, the reductions in R&D are likely from better manufacturing and patient selection, not just refinement in trial and general R&D expenditure.

[Dan Sfera @Dansfera]

$AQST at current valuations we are getting for FREE: libervant, aqst-108, and if you studied the stock at all, anaphylm crushing the prescriptions. This stock still priced liked a pre commercial risk on venture